News By: Gary Cramer

Protocol amendments have evolved from an expected operational reality to a defining factor in clinical trial performance, cost, and site sustainability. Across sponsor, contract research organization, and site stakeholders, a consistent message is emerging: while amendments are often necessary, their frequency, timing, and execution are introducing significant downstream inefficiencies. The evidence is clear: protocol amendments are now a system-level challenge requiring coordinated, industry-wide solutions.

An electronic informed consent (eConsent) working group has developed a high-level framework for defining and measuring the impact of eConsent usage at clinical trial sites. This article outlines key success indicators, relevant metrics, and practical steps the industry can take to begin assessing the real-world impact of eConsent on site operations. As eConsent adoption matures, this high-level framework can evolve into a more complex key performance indicator infrastructure.

An electronic informed consent (eConsent) working group has developed a clear, practical framework that defines the value of integrating eConsent systems with key eClinical technologies. In the companion piece to this article, “Envisioning eConsent Success (Part I): Measuring Operational Impacts at Clinical Trial Sites,” the group defined the different deployment models for eConsent and outlined key stakeholder success measures for using these systems. This article focuses on a technology-agnostic integration blueprint that considers both sponsor-deployed and site-owned systems, and prioritizes both operational feasibility and reduction of duplicate workflows at study sites.

Clinical research has never been more digital, yet for research sites, the cumulative effect of the abundance of digital technologies now available can create a paradox: systems designed to improve efficiency may also introduce substantial administrative burden. This article examines technology fragmentation from a research site perspective and argues that the primary challenge is not digitalization itself, but the lack of integration and standardization across the clinical research ecosystem.

The title for this message, inspired by Marvel Comic’s multi-billion-dollar Avengers movie franchise, is a call to action from ACRP's new Chief Executive Officer. He writes that, like the superhero members of The Avengers, we each bring different capabilities, funds of knowledge, and experiences to the table…and yes, we can occasionally drive each other crazy. We can be successful individually in our own right, but when the stakes are high enough, we assemble. And the stakes are high enough.